Suppr超能文献

肝脏X受体调节剂的治疗机会。

Therapeutic opportunities for liver X receptor modulators.

作者信息

Collins Jon L

机构信息

GlaxoSmithKline Research and Development, Discovery Research, Nuclear Receptor Chemistry, Research Triangle Park, NC 27709, USA.

出版信息

Curr Opin Drug Discov Devel. 2004 Sep;7(5):692-702.

Abstract

The liver X receptors (LXRs), LXRalpha and LXRbeta, are ligand-activated transcription factors of the nuclear receptor superfamily that control the expression of genes involved in cholesterol and fatty acid metabolism. While the identification of small-molecule non-steroidal LXR agonists has validated the LXRs as potential drug targets for cardiovascular disease, recent reports from several research groups suggest that LXR ligands will be valuable therapeutic agents for the treatment of inflammation, diabetes and neurodegenerative diseases. This review focuses on the effects of LXR agonists on relevant signaling pathways, the recently reported ligand-bound LXR crystal structures, and recently disclosed LXR small-molecule templates.

摘要

肝脏X受体(LXRs),即LXRα和LXRβ,是核受体超家族中受配体激活的转录因子,可控制参与胆固醇和脂肪酸代谢的基因表达。虽然小分子非甾体LXR激动剂的鉴定已证实LXRs是心血管疾病的潜在药物靶点,但几个研究小组最近的报告表明,LXR配体将成为治疗炎症、糖尿病和神经退行性疾病的有价值的治疗药物。本文综述聚焦于LXR激动剂对相关信号通路的影响、最近报道的配体结合LXR晶体结构以及最近披露的LXR小分子模板。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验